Data shows nearly 19% weight loss in people with overweight or obesity in Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide (BI 456906)1
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
"Given the prevalence of obesity and its many disease-related complications, there is a dire need for treatments that can help treat the disease of obesity effectively," said Carel le Roux, MD, Ph.D., Professor at University College in Dublin, Ireland, and Principal Investigator of the trial. "Current treatments for obesity mainly focus on weight loss by reducing energy intake.2 By activating both the glucagon and GLP-1 receptors, survodutide may both inhibit appetite and improve energy expenditure, thereby helping to treat the disease of obesity.2 These encouraging data support the further study of survodutide in larger Phase III trials."
"With our long heritage in researching and developing new treatments for cardiovascular, renal, and metabolic conditions, we are extremely encouraged by these robust and compelling Phase II data," said Carinne Brouillon, Head of Human Pharma, Boehringer Ingelheim. "Survodutide may become the first anti-obesity medication to reduce appetite while increasing energy expenditure through the liver. We look forward to furthering our discussions with health authorities to advance this dual receptor agonist into Phase III trials as we aim to help fill a treatment gap in this disease area."
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
INGELHEIM, Germany & COPENHAGEN, Denmark -- Businesswire -- Boehringer Ingelheim and Zealand Pharma A/S (Nasdaq: ZEAL) today announced additional data demonstrating superior efficacy with survodutide (also known as BI 456906) versus placebo in people with overweight or obesity without type 2 diabetes after 46 weeks of treatment.1 The findings were presented at the 2023 American Diabetes Association’s 83rd Scientific Sessions in San Diego, CA, U.S.
The Phase II study included two analyses: planned (assigned dose at randomization, which was also the primary endpoint) and actual (dose at the end of treatment).1 People who completed the study on the 4.8 mg dose (actual treatment analysis) achieved nearly 19% weight loss.1 As previously announced, the planned treatment analysis demonstrated nearly 15% weight loss for all those randomized to the 4.8 mg dose.1 Bodyweight reductions with survodutide had not reached a plateau at week 46, suggesting additional weight loss could be achieved with longer treatment duration.1
“Given the prevalence of obesity and its many disease-related complications, there is a dire need for treatments that can help treat the disease of obesity effectively,” said Carel le Roux, MD, Ph.D., Professor at University College in Dublin, Ireland, and Principal Investigator of the trial. “Current treatments for obesity mainly focus on weight loss by reducing energy intake.2 By activating both the glucagon and GLP-1 receptors, survodutide may both inhibit appetite and improve energy expenditure, thereby helping to treat the disease of obesity.2 These encouraging data support the further study of survodutide in larger Phase III trials.”
After 46 weeks of treatment, up to 40% of people who reached the highest two doses of survodutide achieved a weight loss of at least 20%, versus 0% with placebo.1 Body weight loss of 15% or more was achieved by 67% of people who reached survodutide 4.8 mg versus 4.3% of those on placebo.1
Treatment with survodutide did not show unexpected safety or tolerability issues. Serious adverse events were reported by 4.2% of participants on survodutide versus 6.5% of those on placebo.1 Treatment discontinuation due to adverse events occurred in 24.6% and 3.9% of participants, respectively, mainly due to gastrointestinal adverse events.1 Most treatment discontinuations due to adverse events occurred during the rapid dose-escalation phase and may potentially be mitigated with more gradual dose escalation.1 The adverse events reported were similar to those expected with the GLP1-R agonist class of drugs.1
“With our long heritage in researching and developing new treatments for cardiovascular, renal, and metabolic conditions, we are extremely encouraged by these robust and compelling Phase II data,” said Carinne Brouillon, Head of Human Pharma, Boehringer Ingelheim. “Survodutide may become the first anti-obesity medication to reduce appetite while increasing energy expenditure through the liver. We look forward to furthering our discussions with health authorities to advance this dual receptor agonist into Phase III trials as we aim to help fill a treatment gap in this disease area.”
“Obesity is one of the most significant healthcare challenges in medicine today,” said David Kendall, M.D., Chief Medical Officer, Zealand Pharma. “At Zealand Pharma, we have both experience and success in discovering and developing peptide therapeutics that target key metabolic pathways - designed to help people living with overweight and obesity by achieving substantial weight loss while addressing the many complications of this disease.”
Please click on the following link for ‘Notes to editors’ and ‘References’
https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/obesity/phase-ii-clinical-trial-weight-loss-results
View source version on businesswire.com: https://www.businesswire.com/news/home/20230623791058/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Boehringer Ingelheim
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 삼성전자 ‘삼성 개발자 콘퍼런스 2024’ 개최 - 뉴스와이어
- 국내 최대 시상금 규모… 제1회 삼익 아마추어 콩쿠르 11월 개최 - 뉴스와이어
- 아모레퍼시픽, 프랑스 칸 ‘2024 TFWA 세계면세박람회’ 참가 - 뉴스와이어
- ‘진짜 두바이 초콜릿’이 왔다… 오리지널 중동의 맛 블린더 초콜릿, 한국 정식 출시 - 뉴스와
- GS샵 ‘궁키친 이상민’ 간편식 6개월 만에 누적 판매 60억원 돌파 - 뉴스와이어
- 대한전선, 싱가포르서 8400억 수주 - 뉴스와이어
- 삼성전자, 업계 최고 성능·최대 용량 PC용 SSD PM9E1 양산 - 뉴스와이어
- 좋은땅출판사 ‘주식으로 떠나는 은퇴 여행’ 출간 - 뉴스와이어
- ‘오대꽃밥’ 귀한 꽃으로 피어나는 철원 오대쌀 축제 - 뉴스와이어
- 템퍼, 미국우주재단 인증 26주년 기념 ‘템퍼 유니버스’ 프로모션 진행 - 뉴스와이어